mRNA decay plays an essential role in the control of gene expression in bacteria. Exoribonucleases (exoRNases), which trim transcripts starting from the 5' or 3' end, are particularly important to fully degrade unwanted transcripts and renew the pool of nucleotides available in the cell. While recent techniques have allowed genome-wide identification of ribonuclease (RNase) targets in bacteria in vivo, none of the 3'-to-5' exoRNase targetomes (i.e., global processing sites) have been studied so far. Here, we report the targetomes of YhaM, polynucleotide phosphorylase (PNPase), and RNase R of the human pathogen We determined that YhaM is an unspecific enzyme that trims a few nucleotides and targets the majority of transcript ends, generated either by transcription termination or by endonucleolytic activity. The molecular determinants for YhaM-limited processivity are yet to be deciphered. We showed that PNPase clears the cell from mRNA decay fragments produced by endoribonucleases (endoRNases) and is the major 3'-to-5' exoRNase for RNA turnover in In particular, PNPase is responsible for the degradation of regulatory elements from 5' untranslated regions. However, we observed little RNase R activity in standard culture conditions. Overall, our study sheds light on the very distinct features of 3'-to-5' exoRNases.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6243249 | PMC |
http://dx.doi.org/10.1073/pnas.1809663115 | DOI Listing |
Naunyn Schmiedebergs Arch Pharmacol
December 2024
Department of Pharmaceutical Sciences and Technology, Birla Institute of Technology, Mesra, Ranchi, Jharkhand, India.
Idiopathic pulmonary fibrosis (IPF) is a severe and progressive lung disorder with an average survival rate of 3 to 5 years. IPF presents a significant challenge in clinical management, necessitating novel therapeutic approaches. Nanostructured lipid carriers (NLCs) have proven to be promising vehicles for targeted drug delivery to the lung tissues.
View Article and Find Full Text PDFAntimicrob Agents Chemother
December 2024
Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA.
Sulbactam-durlobactam is approved for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by susceptible isolates of complex. Patients with serious infections may require support with continuous renal replacement therapy (CRRT), which presents challenges for optimal dosing of antibiotics. Sulbactam-durlobactam dosing regimens were derived for this population using an CRRT model and Monte Carlo simulation (MCS).
View Article and Find Full Text PDFThe Tree Crickets of the genus Oecanthus Serville, 1831 are distributed across tropical and temperate regions, where they can be found in all strata of vegetation. In this work, we describe a new species of tree cricket from the Brazilian Amazon rainforest, where only one species was known until the date of this publication. This new species differs from the other 79 species in this genus by the absence of marks on the scape and pedicel of the antennae, as well as by its calling song composed of 3 to 5 chirps/s, 6 to 20 pulses per chirp, and peak frequency 3 to 3.
View Article and Find Full Text PDFAm J Transl Res
September 2024
Department of Cardiology, The First Affiliated Hospital, Jinan University Guangzhou 510630, Guangdong, China.
Fluids Barriers CNS
September 2024
Axoltis Pharma, 60 avenue Rockefeller, Lyon, 69008, France.
Background: Alterations of blood-brain barrier (BBB) and blood-spinal cord barrier have been documented in various animal models of neurodegenerative diseases and in patients. Correlations of these alterations with functional deficits suggest that repairing barriers integrity may represent a disease-modifying approach to prevent neuroinflammation and neurodegeneration induced by the extravasation of blood components into the parenchyma. Here, we screened the effect of a subcommissural organ-spondin-derived peptide (NX210c), known to promote functional recovery in several models of neurological disorders, on BBB integrity in vitro and in vivo.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!